JP2011525523A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011525523A5 JP2011525523A5 JP2011515372A JP2011515372A JP2011525523A5 JP 2011525523 A5 JP2011525523 A5 JP 2011525523A5 JP 2011515372 A JP2011515372 A JP 2011515372A JP 2011515372 A JP2011515372 A JP 2011515372A JP 2011525523 A5 JP2011525523 A5 JP 2011525523A5
- Authority
- JP
- Japan
- Prior art keywords
- fviii
- buffer
- ligand
- resin
- multimodal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 25
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 19
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 19
- 239000003446 ligand Substances 0.000 claims 9
- 239000011347 resin Substances 0.000 claims 7
- 229920005989 resin Polymers 0.000 claims 7
- 230000002779 inactivation Effects 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 238000000746 purification Methods 0.000 claims 5
- 125000000129 anionic group Chemical group 0.000 claims 4
- 239000012539 chromatography resin Substances 0.000 claims 4
- 230000003993 interaction Effects 0.000 claims 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 239000000872 buffer Substances 0.000 claims 3
- 239000012928 buffer substance Substances 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000003599 detergent Substances 0.000 claims 3
- 239000012149 elution buffer Substances 0.000 claims 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 150000002894 organic compounds Chemical class 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- 238000011210 chromatographic step Methods 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 239000011534 wash buffer Substances 0.000 claims 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims 1
- WOUANPHGFPAJCA-UHFFFAOYSA-N 2-[benzyl(methyl)amino]ethanol Chemical compound OCCN(C)CC1=CC=CC=C1 WOUANPHGFPAJCA-UHFFFAOYSA-N 0.000 claims 1
- OACIMSFRSUBGQU-UHFFFAOYSA-N 2-benzamidobutanoic acid Chemical compound CCC(C(O)=O)NC(=O)C1=CC=CC=C1 OACIMSFRSUBGQU-UHFFFAOYSA-N 0.000 claims 1
- VBAOEVKQBLGWTH-UHFFFAOYSA-N 2-pyridin-4-ylethanethiol Chemical compound SCCC1=CC=NC=C1 VBAOEVKQBLGWTH-UHFFFAOYSA-N 0.000 claims 1
- PWLKDZUOOBKOAW-UHFFFAOYSA-N 3-[3-methyl-5-(oxolan-2-ylmethylamino)anilino]benzoic acid Chemical compound C=1C(NC=2C=C(C=CC=2)C(O)=O)=CC(C)=CC=1NCC1CCCO1 PWLKDZUOOBKOAW-UHFFFAOYSA-N 0.000 claims 1
- 239000007995 HEPES buffer Substances 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 239000007987 MES buffer Substances 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 239000013504 Triton X-100 Substances 0.000 claims 1
- 229920004890 Triton X-100 Polymers 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 238000001042 affinity chromatography Methods 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003957 anion exchange resin Substances 0.000 claims 1
- 238000010936 aqueous wash Methods 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 238000005341 cation exchange Methods 0.000 claims 1
- 239000003729 cation exchange resin Substances 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 239000000356 contaminant Substances 0.000 claims 1
- 238000010828 elution Methods 0.000 claims 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 229910017053 inorganic salt Inorganic materials 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000012433 multimodal chromatography Methods 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 125000004344 phenylpropyl group Chemical group 0.000 claims 1
- 230000001766 physiological effect Effects 0.000 claims 1
- 229920001993 poloxamer 188 Polymers 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 1
- 239000012266 salt solution Substances 0.000 claims 1
- 238000001542 size-exclusion chromatography Methods 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12940208P | 2008-06-24 | 2008-06-24 | |
| EP08158893.1 | 2008-06-24 | ||
| EP08158893 | 2008-06-24 | ||
| US61/129,402 | 2008-06-24 | ||
| PCT/EP2009/057883 WO2009156430A1 (en) | 2008-06-24 | 2009-06-24 | A process of purifying coagulation factor viii |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011525523A JP2011525523A (ja) | 2011-09-22 |
| JP2011525523A5 true JP2011525523A5 (https=) | 2012-08-09 |
| JP5619738B2 JP5619738B2 (ja) | 2014-11-05 |
Family
ID=40076764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011515372A Active JP5619738B2 (ja) | 2008-06-24 | 2009-06-24 | 凝固第ｖｉｉｉ因子の精製方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8329871B2 (https=) |
| EP (2) | EP2300497B1 (https=) |
| JP (1) | JP5619738B2 (https=) |
| KR (3) | KR20160104740A (https=) |
| CN (1) | CN102066417B (https=) |
| AU (1) | AU2009264282B2 (https=) |
| BR (1) | BRPI0914695B1 (https=) |
| CA (1) | CA2728047C (https=) |
| DK (2) | DK2300497T3 (https=) |
| ES (2) | ES2391613T3 (https=) |
| IL (3) | IL229583B (https=) |
| MX (1) | MX2010013908A (https=) |
| PL (1) | PL2300497T3 (https=) |
| PT (1) | PT2300497E (https=) |
| RU (2) | RU2698392C2 (https=) |
| SI (1) | SI2300497T1 (https=) |
| UA (1) | UA100901C2 (https=) |
| WO (1) | WO2009156430A1 (https=) |
| ZA (1) | ZA201009162B (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8399620B2 (en) | 2007-07-11 | 2013-03-19 | Novo Nordisk A/S | Purification of factor VIII using a mixed-mode or multimodal resin |
| EP2027875A1 (en) * | 2007-08-23 | 2009-02-25 | Octapharma AG | A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC) |
| CN102119172A (zh) | 2008-08-21 | 2011-07-06 | 奥克塔法马股份有限公司 | 重组制备的人类因子viii和ix |
| US20110178019A1 (en) * | 2008-09-03 | 2011-07-21 | Brita Rippner | New protecting compositions for recombinantly produced factor viii |
| US20110166332A1 (en) * | 2008-09-12 | 2011-07-07 | Ge Healthcare Bio-Sciences Ab | Enhanced antibody aggregate removal with capto adhere in the presence of protein-excluded zwitterions |
| DK2552948T3 (en) * | 2010-03-30 | 2016-10-17 | Octapharma Ag | A process for the purification of the protein growth factor G-CSF |
| EP2553095B1 (en) * | 2010-03-30 | 2016-10-12 | Octapharma AG | A process for purifying vitamin K dependent proteins such as coagulation factor IX |
| AU2011244348B2 (en) | 2010-04-20 | 2015-02-12 | Octapharma Ag | New stabilizing agent for pharmaceutical proteins |
| WO2012049285A1 (en) | 2010-10-14 | 2012-04-19 | Octapharma Ag | A method for the quantitative glycosylation analysis of proteins |
| RU2591523C2 (ru) * | 2010-11-05 | 2016-07-20 | Ф. Хоффманн-Ля Рош Аг | Оптимизированный метод захвата антител хроматографией смешанного типа |
| RU2600886C2 (ru) * | 2011-05-13 | 2016-10-27 | Октафарма Аг | Способ повышения продуктивности эукариотических клеток в продуцировании рекомбинантного fviii |
| JP5640189B2 (ja) | 2011-06-17 | 2014-12-17 | 学校法人東日本学園 | ループスアンチコアグラント検出用血液凝固時間の測定方法 |
| US20130109807A1 (en) * | 2011-10-26 | 2013-05-02 | Bio-Rad Laboratories, Inc. | Removal of virucidal agents in mixed mode chromatography |
| US20150275195A1 (en) * | 2012-10-24 | 2015-10-01 | Genzyme Corporation | Elution of biomolecules from multi-modal resins using mes and mops as mobile phase modifiers |
| US20140154233A1 (en) | 2012-12-05 | 2014-06-05 | Csl Limited | Method of purifying therapeutic proteins |
| US10188965B2 (en) | 2012-12-05 | 2019-01-29 | Csl Behring Gmbh | Hydrophobic charge induction chromatographic depletion of a protein from a solution |
| CN103880947B (zh) * | 2012-12-21 | 2016-01-13 | 武汉禾元生物科技股份有限公司 | 一种分离纯化高纯度重组人血清白蛋白的层析方法 |
| SG10201709131UA (en) * | 2013-03-08 | 2017-12-28 | Genzyme Corp | Continuous purification of therapeutic proteins |
| EP3008085A4 (en) * | 2013-06-13 | 2017-05-10 | Biogen MA Inc. | Anti-factor viii antibodies or uses thereof |
| WO2015005960A1 (en) | 2013-07-12 | 2015-01-15 | Emd Millipore Corporation | Removal of fragments from a sample containing a target protein using activated carbon |
| WO2015021423A2 (en) * | 2013-08-08 | 2015-02-12 | Biogen Idec Ma Inc. | Purification of chimeric fviii molecules |
| MY173548A (en) | 2013-09-24 | 2020-02-04 | Pfizer | Fxa variant compositions |
| TWI709569B (zh) | 2014-01-17 | 2020-11-11 | 美商健臻公司 | 無菌層析樹脂及其用於製造方法的用途 |
| TWI671312B (zh) * | 2014-01-17 | 2019-09-11 | 美商健臻公司 | 無菌層析法及製法 |
| RU2695428C2 (ru) * | 2014-01-20 | 2019-07-23 | Октафарма Аг | СПОСОБ ПРОИЗВОДСТВА ФАКТОРА VIII, ИМЕЮЩЕГО УЛУЧШЕННОЕ СООТНОШЕНИЕ FVIII:C/FVIII:Ag |
| EP3097188B1 (en) * | 2014-01-24 | 2018-08-29 | AM-Pharma B.V. | Downstream processing of an alkaline phosphatase |
| KR102382402B1 (ko) | 2014-02-04 | 2022-04-01 | 바이오젠 엠에이 인코포레이티드 | 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도 |
| CN104861060A (zh) * | 2014-02-21 | 2015-08-26 | 神州细胞工程有限公司 | 一种纯化凝血因子viii的方法 |
| KR20170010750A (ko) | 2014-05-29 | 2017-02-01 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 단백질 추출 방법들 |
| US10626164B2 (en) * | 2014-07-25 | 2020-04-21 | Csl Limited | Purification of VWF |
| GB201506113D0 (en) | 2015-04-10 | 2015-05-27 | Ge Healthcare Bio Sciences Ab | Method for chromatography |
| GB201506117D0 (en) * | 2015-04-10 | 2015-05-27 | Ge Healthcare Bio Sciences Ab | Method for chromatography |
| WO2016207328A1 (en) * | 2015-06-24 | 2016-12-29 | Glycotope Gmbh | PROCESS FOR THE PURIFICATION OF γ-CARBOXYLATED POLYPEPTIDES |
| EP3205665A1 (en) | 2016-02-11 | 2017-08-16 | Octapharma AG | Method of separating factor viii from blood products |
| GB201617240D0 (en) * | 2016-10-11 | 2016-11-23 | Profactor Pharma Ltd | Purification process |
| EP3642225A1 (en) * | 2017-06-23 | 2020-04-29 | Baxalta Incorporated | Purification of factor viii subspecies |
| CN107226859B (zh) * | 2017-08-10 | 2020-11-24 | 博雅生物制药集团股份有限公司 | 一种人凝血因子ⅷ的制备方法 |
| US11584777B2 (en) | 2017-08-31 | 2023-02-21 | Green Cross Corporation | Method for purifying a sulfatase protein |
| MX2020004151A (es) | 2017-10-30 | 2020-08-13 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos. |
| HK40046210A (en) | 2018-08-31 | 2021-10-29 | Genzyme Corporation | Sterile chromatography resin and use thereof in manufacturing processes |
| TWI787710B (zh) * | 2020-01-20 | 2022-12-21 | 中國大陸商上海藥明生物技術有限公司 | 用於親和層析的新型清洗緩衝液 |
| CN118217951B (zh) * | 2024-04-01 | 2025-05-23 | 山东建筑大学 | 一种水中的高纯度磷回收装置和方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4540573A (en) | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
| US5605884A (en) * | 1987-10-29 | 1997-02-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Factor VIII formulations in high ionic strength media |
| US5316680A (en) | 1992-10-21 | 1994-05-31 | Cornell Research Foundation, Inc. | Multimodal chromatographic separation media and process for using same |
| EP0711485B1 (en) | 1993-06-11 | 1997-04-16 | Nortel Networks Corporation | Method for providing user controlled call management services |
| DE4337573C1 (de) * | 1993-11-04 | 1995-05-18 | Octapharma Ag | Verfahren zur Herstellung einer virusinaktivierten Faktor VIII enthaltenden Fraktion mittels chromatographischer Methoden |
| SE9403915D0 (sv) | 1994-11-14 | 1994-11-14 | Annelie Almstedt | Process A |
| AUPR638801A0 (en) * | 2001-07-13 | 2001-08-09 | Life Therapeutics Limited | Factor viii separation |
| AU2005216847B2 (en) * | 2004-02-27 | 2010-04-01 | Cytiva Bioprocess R&D Ab | A process for the purification of antibodies |
| EP3127916A1 (en) * | 2004-06-07 | 2017-02-08 | Therapure Biopharma Inc. | Isolation of plasma or serum proteins |
| EP1707634A1 (en) | 2005-03-29 | 2006-10-04 | Octapharma AG | Method for isolation of recombinantly produced proteins |
| FR2887883B1 (fr) * | 2005-06-29 | 2007-08-31 | Lab Francais Du Fractionnement | Procede de separation des proteines fibrinogene, facteur xiii et colle biologique d'une fraction plasmatique solubilisee et de preparation de concentres lyophilises desdites proteines |
| EP1739179A1 (en) | 2005-06-30 | 2007-01-03 | Octapharma AG | Serum-free stable transfection and production of recombinant human proteins in human cell lines |
| US20080125580A1 (en) * | 2006-07-14 | 2008-05-29 | Genentech, Inc. | Refolding of Recombinant Proteins |
| RU2324495C1 (ru) * | 2006-08-31 | 2008-05-20 | Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации | Способ получения препарата фактора свертывания viii крови человека |
| CA2674881A1 (en) * | 2007-02-01 | 2008-08-07 | Baxter International Inc. | Fviii-independent fix-mutant proteins for hemophilia a treatment |
| ES2392569T3 (es) * | 2007-06-13 | 2012-12-11 | Csl Behring Gmbh | Uso de preparaciones FVIII estabilizadas VWF para administración extravascular en la terapia y el tratamiento profiláctico de trastornos de hemorragias |
| US8399620B2 (en) | 2007-07-11 | 2013-03-19 | Novo Nordisk A/S | Purification of factor VIII using a mixed-mode or multimodal resin |
| GB0723712D0 (en) * | 2007-12-04 | 2008-01-16 | Apitope Technology Bristol Ltd | Peptides |
| DE102008032361A1 (de) * | 2008-07-10 | 2010-01-21 | Csl Behring Gmbh | Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie |
-
2009
- 2009-06-24 KR KR1020167023450A patent/KR20160104740A/ko not_active Abandoned
- 2009-06-24 DK DK09769279.2T patent/DK2300497T3/da active
- 2009-06-24 EP EP09769279A patent/EP2300497B1/en active Active
- 2009-06-24 UA UAA201100699A patent/UA100901C2/ru unknown
- 2009-06-24 DK DK12179389.7T patent/DK2537862T3/en active
- 2009-06-24 RU RU2015141849A patent/RU2698392C2/ru active
- 2009-06-24 JP JP2011515372A patent/JP5619738B2/ja active Active
- 2009-06-24 EP EP12179389.7A patent/EP2537862B1/en not_active Revoked
- 2009-06-24 WO PCT/EP2009/057883 patent/WO2009156430A1/en not_active Ceased
- 2009-06-24 PL PL09769279T patent/PL2300497T3/pl unknown
- 2009-06-24 BR BRPI0914695-4A patent/BRPI0914695B1/pt active IP Right Grant
- 2009-06-24 CN CN200980123974.6A patent/CN102066417B/zh active Active
- 2009-06-24 SI SI200930362T patent/SI2300497T1/sl unknown
- 2009-06-24 KR KR1020107028866A patent/KR101700722B1/ko active Active
- 2009-06-24 AU AU2009264282A patent/AU2009264282B2/en active Active
- 2009-06-24 CA CA2728047A patent/CA2728047C/en active Active
- 2009-06-24 KR KR1020177024076A patent/KR101804136B1/ko active Active
- 2009-06-24 RU RU2011102437/10A patent/RU2567811C2/ru active
- 2009-06-24 PT PT09769279T patent/PT2300497E/pt unknown
- 2009-06-24 US US12/737,230 patent/US8329871B2/en active Active
- 2009-06-24 ES ES09769279T patent/ES2391613T3/es active Active
- 2009-06-24 ES ES12179389.7T patent/ES2538706T3/es active Active
- 2009-06-24 MX MX2010013908A patent/MX2010013908A/es active IP Right Grant
-
2010
- 2010-12-05 IL IL229583A patent/IL229583B/en active IP Right Grant
- 2010-12-05 IL IL209758A patent/IL209758A/en active IP Right Grant
- 2010-12-21 ZA ZA2010/09162A patent/ZA201009162B/en unknown
-
2013
- 2013-11-24 IL IL229583A patent/IL229583A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011525523A5 (https=) | ||
| RU2011102437A (ru) | Способ очистки фактора свертывания крови viii | |
| CA2784278C (en) | Wash solution and method for affinity chromatography | |
| CN101730707B (zh) | 使用混合式或多模式树脂来纯化因子ⅷ | |
| CN102858971B (zh) | 纯化维生素k依赖性蛋白如凝血因子ix的方法 | |
| CN1163600C (zh) | 人胰岛素原的制备方法 | |
| JP2013500711A5 (https=) | ||
| RU2015149979A (ru) | Способ очистки белка фактора роста | |
| JPWO2015041218A1 (ja) | 新規抗体精製方法及びそれから得られる抗体（ＮｏｖｅｌＡｎｔｉｂｏｄｙＰｕｒｉｆｉｃａｔｉｏｎＭｅｔｈｏｄａｎｄＡｎｔｉｂｏｄｙｏｂｔａｉｎｅｄｔｈｅｒｅｆｒｏｍ）、並びに陽イオン交換基を用いた新規抗体精製法及びそれから得られる抗体（ＮｏｖｅｌＡｎｔｉｂｏｄｙＰｕｒｉｆｉｃａｔｉｏｎｍｅｔｈｏｄｕｓｉｎｇＣａｔｉｏｎＥｘｃｈａｎｇｅｒａｎｄＡｎｔｉｂｏｄｙｏｂｔａｉｎｅｄｔｈｅｒｅｆｒｏｍ） | |
| ES2552337T3 (es) | Procedimientos para la preparación de plasminógeno | |
| JP2019528255A5 (https=) | ||
| US20240025950A1 (en) | Method of purification of recombinantly-produced rsv proteins in trimeric form | |
| WO1995004077A1 (en) | Method of purifying plasminogen | |
| CN103282045A (zh) | 因子viii水溶液 | |
| CN109803982A (zh) | Fviii的纯化过程 | |
| JP2017517514A (ja) | Ｈｍｇ−ｕｐ（超高純度グレードのヒト閉経期ゴナドトロピン）を得るための方法及び夾雑物を含まない組成物 | |
| EA040179B1 (ru) | Способ очистки fviii или его варианта с удаленным доменом b от клеточной культуры in vitro |